On June 30, 2020, Bruemmendorf, Tim H.; Gambacorti-Passerini, Carlo; Bushmakin, Andrew G.; Cappelleri, Joseph C.; Viqueira, Andrea; Reisman, Arlene; Isfort, Susanne; Mamolo, Carla published an article.Formula: C26H29Cl2N5O3 The title of the article was Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia. And the article contained the following:
Abstract: Patients with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) can be effectively treated with tyrosine kinase inhibitors (TKIs) and achieve a lifespan similar to the general population. The success of TKIs, however, requires long-term and sometimes lifelong treatment; thus, patient-assessed health-related quality of life (HRQoL) has become an increasingly important parameter for treatment selection. Bosutinib is a TKI approved for CP CML in newly diagnosed adults and in those resistant or intolerant to prior therapy. In the Bosutinib Trial in First-Line Chronic Myelogenous Leukemia Treatment (BFORE), bosutinib demonstrated a significantly higher major mol. response rate compared with imatinib, with maintenance of HRQoL (measured by the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) questionnaire), after 12 mo of first-line treatment. We examined relationships between mol. response (MR) and HRQoL. MR values were represented by a log-reduction scale (MRLR; a continuous variable). A repeated-measures longitudinal model was used to estimate the relationships between MRLR as a predictor and each FACT-Leu domain as an outcome. Effect sizes were calculated to determine strength of effects and allow comparisons across domains. The majority of FACT-Leu domains (with the exception of social well-being and phys. well-being) demonstrated a significant relationship with MRLR (p < 0.05). Our results showed variable impact of clin. improvement on different dimensions of HRQoL. For patients who achieved MR5, emotional well-being and leukemia-specific domains showed the greatest improvement, with medium differences in effect sizes, whereas social well-being and phys. well-being had the weakest relationship with MR. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Formula: C26H29Cl2N5O3
The Article related to bosutinib imatinib antileukemic agent diagnosis chronic myeloid leukemia, bosutinib, chronic myeloid leukemia, health-related quality of life, imatinib, molecular response and other aspects.Formula: C26H29Cl2N5O3
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics